Determination of Cellular and Clinical Thresholds for IgE-Mediated Reactivity
IgE 介导的反应性的细胞和临床阈值的确定
基本信息
- 批准号:7666134
- 负责人:
- 金额:$ 28.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAffectAirway ResistanceAllergensAllergicAllergic ReactionAllergic rhinitisAnaphylaxisAntibodiesAntibody TherapyBasophilsBindingBiochemical MarkersBiological MarkersBiologyBiopsyBloodBronchial Provocation TestsCellsChestClinicalCollaborationsCytologyDataDetectionDiagnostic testsDouble-Blind MethodEpithelialEvaluationFelis catusFoodFood HypersensitivityGoalsHalf-LifeHistamineHistamine ReleaseHourHypersensitivity skin testingIgEIn VitroInhalant dose formInsect StingIrrigationKineticsKnowledgeLaboratoriesLearningLeukocytesLungLymphocyteMeasurementMeasuresMediatingMediator of activation proteinModelingMonitorNoseNumbersOralOutcomePharmaceutical PreparationsPhasePhysiologicalPlacebosPlayPrincipal InvestigatorProcessProductionProstaglandin D2Protocols documentationReactionRecrudescencesRecruitment ActivityRelative (related person)RoleScoreSerumSeveritiesSiteSkinSubgroupSurfaceSymptomsTestingTimeTissuesTryptaseWeekbasecell typechemokineclinically relevantdaydensityeosinophilfallsin vitro Assayin vivomast cellomalizumabplacebo controlled studyprogramsresponseselective expressiontooltrafficking
项目摘要
While the detection of allergen-specific IgE, either by skin testing or in vitro assays, is a useful marker of
allergic sensitivity, the relationship between specific IgE levels and allergic responses is far from clear. In
fact, for food, drug, insect sting and inhalant allergens most studies have shown no relationship between
the levels of specific IgE and type or severity of responses to allergen exposure. The lack of such a
relationship may be due to a variety of factors that we propose to investigate in the clinical and ex vivo
studies described in this project. A central hypothesis to be tested is that a combination of the allergen-specific
IgE and total IgE levels, especially the ratio of these two measurements, by influencing FceRI
occupancy and density, determines the threshold and likelihood for cellular and clinical reactivity. This
hypothesis is based in part on what our group and other laboratories have learned about how IgE, and an
FDA-approved IgE-lowering antibody therapy, omalizumab, regulates basophil and mast cell
responsiveness and surface density of FceRI. Given the half-life of mast cells in different tissue
compartments and the slower onset of action of omalizumab on mast cells compared to that for basophils,
we propose to test the hypothesis that food-induced anaphylaxis and late phase responses are basophildependent
responses by performing skin, airway and oral allergen challenge within the first two weeks,
and after months, of omalizumab administration. We also hypothesize that mechanisms responsible for
trafficking of eosinophils to sites of airway late phase responses involve IgE-mediated triggering of
recruited basophils, which then release mediators capable of activating epithelial chemokine production
selective for eosinophils. As part of these efforts, we propose to develop a new and reliable diagnostic test
for the measurement of free total serum IgE levels in collaboration with colleagues in Core B. Our overall
goal is to expand our knowledge of the biology of IgE and its clinical relevance using an approved anti-lgE
antibody, omalizumab, as a mechanistic tool to modulate free IgE levels.
虽然通过皮肤测试或体外测定检测过敏原特异性IgE是过敏性鼻炎的有用标志物,
虽然过敏性反应的发生与特异性IgE水平有关,但特异性IgE水平与过敏反应之间的关系尚不清楚。在
事实上,对于食物、药物、昆虫叮咬和吸入性过敏原,大多数研究表明,
特异性IgE水平和过敏原暴露反应的类型或严重程度。缺乏这种
这种关系可能是由于各种因素,我们建议在临床和体外研究,
该项目中描述的研究。一个有待检验的中心假设是,
IgE和总IgE水平,特别是这两种测量值的比值,通过影响FceRI
占据率和密度决定了细胞和临床反应性的阈值和可能性。这
这一假设部分是基于我们的团队和其他实验室已经了解到的关于IgE和一种
FDA批准的降低IgE抗体疗法奥马珠单抗可调节嗜碱性粒细胞和肥大细胞
FceRI的反应性和表面密度。鉴于肥大细胞在不同组织中的半衰期
与嗜碱性粒细胞相比,奥马珠单抗对肥大细胞的作用起效较慢,
我们建议检验食物引起的过敏反应和晚期反应是嗜碱性粒细胞依赖性的假说
通过在前两周内进行皮肤、气道和口腔过敏原激发,
以及数月后给予奥马珠单抗。我们还假设,
嗜酸性粒细胞向气道晚期反应部位的运输涉及IgE介导的
募集嗜碱性粒细胞,然后释放能够激活上皮趋化因子产生的介质
对嗜酸性粒细胞有选择性。作为这些努力的一部分,我们建议开发一种新的可靠的诊断测试
与核心B的同事合作测量游离总血清IgE水平。我们的整体
我们的目标是扩大我们的知识的生物学IgE及其临床相关性使用批准的抗IgE
抗体奥马珠单抗作为调节游离IgE水平的机制工具。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bruce S Bochner其他文献
Bruce S Bochner的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bruce S Bochner', 18)}}的其他基金
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cells
利用 Siglec-6 将靶向抗过敏药物输送到人体肥大细胞中
- 批准号:
10368109 - 财政年份:2021
- 资助金额:
$ 28.48万 - 项目类别:
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cells
利用 Siglec-6 将靶向抗过敏药物输送到人体肥大细胞中
- 批准号:
10194041 - 财政年份:2021
- 资助金额:
$ 28.48万 - 项目类别:
Using siglecs and their ligands to treat allergic diseases SALTAD
使用siglecs及其配体治疗过敏性疾病SALTAD
- 批准号:
10331722 - 财政年份:2018
- 资助金额:
$ 28.48万 - 项目类别:
Defining Siglec-6 and Siglec-8 function on effector cells of allergic diseases
定义 Siglec-6 和 Siglec-8 对过敏性疾病效应细胞的功能
- 批准号:
10097994 - 财政年份:2018
- 资助金额:
$ 28.48万 - 项目类别:
Using siglecs and their ligands to treat allergic diseases SALTAD
使用siglecs及其配体治疗过敏性疾病SALTAD
- 批准号:
10097976 - 财政年份:2018
- 资助金额:
$ 28.48万 - 项目类别:
Defining Siglec-6 and Siglec-8 function on effector cells of allergic diseases
定义 Siglec-6 和 Siglec-8 对过敏性疾病效应细胞的功能
- 批准号:
10331725 - 财政年份:2018
- 资助金额:
$ 28.48万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 28.48万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 28.48万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 28.48万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 28.48万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 28.48万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 28.48万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 28.48万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 28.48万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 28.48万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 28.48万 - 项目类别:
Research Grant